CIT-话题@MedSci

#CIT#

176篇内容 | 3530人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738578, encodeId=4e151e385785f, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=39, createdTime=2020-11-07, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738571, encodeId=9ebf1e3857162, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, objectType=article, longId=187166, objectId=2f3218e16658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f3218e16658, replyNumber=0, likeNumber=71, createdTime=2020-06-23, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f3218e16658, moduleTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f3218e16658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738569, encodeId=f5fd1e3856942, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Incyte宣布JAK1抑制剂Itacitinib在移植物抗宿主病患者中的3期研究结果, objectType=article, longId=185644, objectId=baa51856448b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baa51856448b, replyNumber=0, likeNumber=69, createdTime=2020-02-19, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baa51856448b, moduleTitle=Incyte宣布JAK1抑制剂Itacitinib在移植物抗宿主病患者中的3期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baa51856448b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738580, encodeId=6e111e3858049, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, objectType=article, longId=196771, objectId=6ae3196e71e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ae3196e71e3, replyNumber=0, likeNumber=63, createdTime=2020-10-09, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ae3196e71e3, moduleTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ae3196e71e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738566, encodeId=14191e3856667, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, objectType=article, longId=180178, objectId=8f301801e8b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f301801e8b0, replyNumber=0, likeNumber=95, createdTime=2019-11-09, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f301801e8b0, moduleTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f301801e8b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738576, encodeId=35da1e3857608, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, objectType=article, longId=191734, objectId=89b6191e3439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b6191e3439, replyNumber=0, likeNumber=60, createdTime=2021-01-08, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b6191e3439, moduleTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b6191e3439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738568, encodeId=42e91e3856876, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, objectType=article, longId=185333, objectId=36af18533328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af18533328, replyNumber=0, likeNumber=67, createdTime=2020-10-14, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af18533328, moduleTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af18533328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738562, encodeId=1f7d1e385627a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Citryll融资1500万欧元开发中和中性粒细胞外陷阱（NETs）的抗体，治疗自身免疫性疾病, objectType=article, longId=174935, objectId=c6061e49351e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6061e49351e, replyNumber=0, likeNumber=111, createdTime=2020-01-13, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6061e49351e, moduleTitle=Citryll融资1500万欧元开发中和中性粒细胞外陷阱（NETs）的抗体，治疗自身免疫性疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6061e49351e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738554, encodeId=dbbb1e385548f, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性, objectType=article, longId=165382, objectId=9da8165382e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9da8165382e2, replyNumber=0, likeNumber=96, createdTime=2019-06-29, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9da8165382e2, moduleTitle=Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9da8165382e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738574, encodeId=27a81e3857481, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, objectType=article, longId=190457, objectId=fbcc19045e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbcc19045e07, replyNumber=0, likeNumber=69, createdTime=2020-05-12, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbcc19045e07, moduleTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbcc19045e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738572, encodeId=f70b1e38572ad, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, objectType=article, longId=188799, objectId=77e1188e9962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77e1188e9962, replyNumber=0, likeNumber=57, createdTime=2020-07-31, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77e1188e9962, moduleTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77e1188e9962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738570, encodeId=bd691e385700c, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症, objectType=article, longId=186909, objectId=12e1186909d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12e1186909d9, replyNumber=0, likeNumber=70, createdTime=2020-02-08, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12e1186909d9, moduleTitle=JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12e1186909d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738567, encodeId=4d5f1e3856776, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Lancet：Upadacitinib治疗强直性脊柱炎效果显著, objectType=article, longId=182959, objectId=eaac182959cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaac182959cb, replyNumber=0, likeNumber=79, createdTime=2020-05-14, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaac182959cb, moduleTitle=Lancet：Upadacitinib治疗强直性脊柱炎效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaac182959cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738547, encodeId=d96c1e385477f, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|侯玉清：NSTE-ACS介入治疗的时机与策略, objectType=article, longId=163323, objectId=c44216332395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c44216332395, replyNumber=0, likeNumber=59, createdTime=2019-04-09, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c44216332395, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|侯玉清：NSTE-ACS介入治疗的时机与策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c44216332395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738548, encodeId=b6ed1e38548a1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|葛均波：冠状动脉微栓塞的研究进展——从基础到临床, objectType=article, longId=163326, objectId=3f361633261c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f361633261c, replyNumber=0, likeNumber=86, createdTime=2019-10-05, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f361633261c, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|葛均波：冠状动脉微栓塞的研究进展——从基础到临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f361633261c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738542, encodeId=afb31e3854240, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, objectType=article, longId=160893, objectId=8353160893a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8353160893a6, replyNumber=0, likeNumber=66, createdTime=2019-12-14, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8353160893a6, moduleTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8353160893a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738561, encodeId=f9431e38561ff, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=全新CiteScore出炉啦！一手资料尽在MedSci期刊数据库, objectType=article, longId=168633, objectId=05a5168633c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05a5168633c8, replyNumber=0, likeNumber=34, createdTime=2020-04-21, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05a5168633c8, moduleTitle=全新CiteScore出炉啦！一手资料尽在MedSci期刊数据库, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05a5168633c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738563, encodeId=22a51e3856307, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, objectType=article, longId=175230, objectId=0b961e52306e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b961e52306e, replyNumber=0, likeNumber=65, createdTime=2019-11-27, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b961e52306e, moduleTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b961e52306e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738555, encodeId=3ad51e385557d, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征, objectType=article, longId=165485, objectId=0adb1654850e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0adb1654850e, replyNumber=0, likeNumber=70, createdTime=2019-08-28, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0adb1654850e, moduleTitle=Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0adb1654850e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738545, encodeId=6ba61e3854576, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019）|于波：ST段抬高型心肌梗死冠状动脉内成像研究的新发现, objectType=article, longId=163293, objectId=4828163293be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4828163293be, replyNumber=0, likeNumber=62, createdTime=2019-11-20, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4828163293be, moduleTitle=第十七届中国介入心脏病学大会（CIT2019）|于波：ST段抬高型心肌梗死冠状动脉内成像研究的新发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4828163293be)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CIT

2020-05-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-11-07

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

2020-06-23

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Incyte宣布JAK1抑制剂Itacitinib在移植物抗宿主病患者中的3期研究结果

2020-02-19

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著

2020-10-09

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功

2019-11-09

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌

2021-01-08

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA

2020-10-14

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Citryll融资1500万欧元开发中和中性粒细胞外陷阱（NETs）的抗体，治疗自身免疫性疾病

2020-01-13

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性

2019-06-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号

2020-05-12

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险

2020-07-31

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症

2020-02-08

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Lancet：Upadacitinib治疗强直性脊柱炎效果显著

2020-05-14

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|侯玉清：NSTE-ACS介入治疗的时机与策略

2019-04-09

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|葛均波：冠状动脉微栓塞的研究进展——从基础到临床

2019-10-05

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请

2019-12-14

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

全新CiteScore出炉啦！一手资料尽在MedSci期刊数据库

2020-04-21

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验

2019-11-27

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征

2019-08-28

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019）|于波：ST段抬高型心肌梗死冠状动脉内成像研究的新发现

2019-11-20

科室
- - 订阅+
  - 更多科室
工具
服务